Clinical Research
Exelixis Announces Further Expansion to Clinical Research Protocol for Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Anti-PD-L1 Immunotherapy
Exelixis
PR-M06-18-NI-024Jun 06, 2018
NDA
Exelixis Announces U.S. FDA Accepts Supplemental New Drug Application for CABOMETYX® (cabozantinib) in Previously Treated Advanced Hepatocellular Carcinoma
Exelixis
PR-M06-18-NI-003Jun 01, 2018